You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表现》康宁杰瑞(09966.HK)暗盘收12.76元 高上市价25%每手赚2,560元
阿思达克 12-11 18:35

根据辉立交易平台显示,明天挂牌的康宁杰瑞制药-B(09966.HK)暗盘开报11.5元,高低分别见13.2元/11.02元,收报12.76元,较上市价10.2元,高25.1%或2.56元;成交2,490万股,涉资3.02亿元。不计手续费,每手1,000股账面赚2,560元。

康宁杰瑞为一家内地领先的临床阶段、未获盈利的生物科技公司。是次来港上市共发售约1.794亿股,并已引入七名基石投资者,分别为Matthews Funds、OrbiMed Funds、Greenwoods、大摩亚洲、清池资本、绿叶制药(02186.HK)及泰康人寿,合共认购8,970.1万股;10%公开发售获逾191倍超购,已启动回拨机制占比增至50%,认购一手中签率40%;股份以招股范围(9.1-10.2元)上限定价,料集资净额约17.09亿元,主要用作关键药物开发项目及苏州新制造及研发设施建设等。上市联席保荐人分别为大摩、中信里昂证券及杰富瑞。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account